EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
EXELIXIS, INC.
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $16.28B
- P/E (TTM)
- 19.7
- Dividend yield
- –
Share price
+$23.43 (+59.69%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
EXELIXIS, INC. grew revenue 9.2% to $2.44B over the twelve months to Jul 3, 2026. Operating income rose 38.8% to $971.51M, moving the operating margin from 31.4% to 39.9%. Free cash flow was $1.17B, up 55.5% from a year earlier.
Revenue
$2.44B
+9.2% vs. a year earlier
Operating income
$971.51M
+38.8% vs. a year earlier
Free cash flow
$1.17B
+55.5% vs. a year earlier
EPS, diluted
$3.18
+52.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 3, 2026
Valuation
- Market cap
- $16.28B
- P/E ratio
- 19.7
- Price to sales
- 6.68
- Price to book
- 8.83
- Dividend yield
- –
- Free cash flow yield
- 7.20%
Fundamentals
- Revenue
- $2.44B
- Net income
- $860.62M
- EPS, diluted
- $3.18
- Free cash flow
- $1.17B
- Book value per share
- $7.10
- Diluted shares
- 260M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$2.44B+9.2% YoY
Gross profit
$2.35B+9.1% YoY
Operating income
$971.51M+38.8% YoY
Net income
$860.62M+42.9% YoY
EPS, diluted
$3.18+52.9% YoY
Free cash flow
$1.17B+55.5% YoY
Reported periodTrailing twelve months